Effect of COVID-19 medications on corrected QT interval and induction of torsade de pointes: Results of a multicenter national survey.
Journal
International journal of clinical practice
ISSN: 1742-1241
Titre abrégé: Int J Clin Pract
Pays: India
ID NLM: 9712381
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
02
02
2021
pubmed:
25
3
2021
medline:
10
7
2021
entrez:
24
3
2021
Statut:
ppublish
Résumé
There are some data showing that repurposed drugs used for the Coronavirus disease-19 (COVID-19) have potential to increase the risk of QTc prolongation and torsade de pointes (TdP), and these arrhythmic side effects have not been adequately addressed in COVID-19 patients treated with these repurposed medications. This is the prospective study of 2403 patients hospitalised at 13 hospitals within the COVID-19 epicentres of the Iran. These patients were treated with chloroquine, hydroxychloroquine, lopinavir/ritonavir, atazanavir/ritonavir, oseltamivir, favipiravir and remdesivir alone or in combination with azithromycin. The primary outcome of the study was incidence of critical QTc prolongation, and secondary outcomes were incidences of TdP and death. Of the 2403 patients, 2365 met inclusion criteria. The primary outcome of QTc ≥ 500 ms and ∆QTc ≥ 60 ms was observed in 11.2% and 17.6% of the patients, respectively. The secondary outcomes of TdP and death were reported in 0.38% and 9.8% of the patients, respectively. The risk of critical QT prolongation increased in the presence of female gender, history of heart failure, treatment with hydroxychloroquine, azithromycin combination therapy, simultaneous furosemide or beta-blocker therapy and acute renal or hepatic dysfunction. However, the risk of TdP was predicted by treatment with lopinavir-ritonavir, simultaneous amiodarone or furosemide administration and hypokalaemia during treatment. This cohort showed significant QTc prolongation with all COVID-19 medications studied, however, life-threatening arrhythmia of TdP occurred rarely. Among the repurposed drugs studied, hydroxychloroquine or lopinavir-ritonavir alone or in combination with azithromycin clearly demonstrated to increase the risk of critical QT prolongation and/or TdP.
Sections du résumé
BACKGROUND
BACKGROUND
There are some data showing that repurposed drugs used for the Coronavirus disease-19 (COVID-19) have potential to increase the risk of QTc prolongation and torsade de pointes (TdP), and these arrhythmic side effects have not been adequately addressed in COVID-19 patients treated with these repurposed medications.
METHODS
METHODS
This is the prospective study of 2403 patients hospitalised at 13 hospitals within the COVID-19 epicentres of the Iran. These patients were treated with chloroquine, hydroxychloroquine, lopinavir/ritonavir, atazanavir/ritonavir, oseltamivir, favipiravir and remdesivir alone or in combination with azithromycin. The primary outcome of the study was incidence of critical QTc prolongation, and secondary outcomes were incidences of TdP and death.
RESULTS
RESULTS
Of the 2403 patients, 2365 met inclusion criteria. The primary outcome of QTc ≥ 500 ms and ∆QTc ≥ 60 ms was observed in 11.2% and 17.6% of the patients, respectively. The secondary outcomes of TdP and death were reported in 0.38% and 9.8% of the patients, respectively. The risk of critical QT prolongation increased in the presence of female gender, history of heart failure, treatment with hydroxychloroquine, azithromycin combination therapy, simultaneous furosemide or beta-blocker therapy and acute renal or hepatic dysfunction. However, the risk of TdP was predicted by treatment with lopinavir-ritonavir, simultaneous amiodarone or furosemide administration and hypokalaemia during treatment.
CONCLUSION
CONCLUSIONS
This cohort showed significant QTc prolongation with all COVID-19 medications studied, however, life-threatening arrhythmia of TdP occurred rarely. Among the repurposed drugs studied, hydroxychloroquine or lopinavir-ritonavir alone or in combination with azithromycin clearly demonstrated to increase the risk of critical QT prolongation and/or TdP.
Identifiants
pubmed: 33759318
doi: 10.1111/ijcp.14182
pmc: PMC8250253
doi:
Substances chimiques
Pharmaceutical Preparations
0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14182Subventions
Organisme : Rajaie Cardiovascular Medical and Research Center
ID : 9962
Informations de copyright
© 2021 John Wiley & Sons Ltd.
Références
Heart Rhythm. 2020 Sep;17(9):1425-1433
pubmed: 32407884
EClinicalMedicine. 2020 Dec;29:100645
pubmed: 33251500
Circulation. 2020 Jun 16;141(24):e906-e907
pubmed: 32267732
Clin Infect Dis. 2020 Jul 28;71(15):732-739
pubmed: 32150618
Circ Cardiovasc Qual Outcomes. 2013 Jul;6(4):479-87
pubmed: 23716032
Travel Med Infect Dis. 2020 Jul - Aug;36:101791
pubmed: 32593867
Circ Arrhythm Electrophysiol. 2020 Jun;13(6):e008662
pubmed: 32347743
Eur Heart J Acute Cardiovasc Care. 2020 Apr;9(3):215-221
pubmed: 32372695
J Electrocardiol. 2020 Nov - Dec;63:115-119
pubmed: 33181454
J Theor Biol. 2008 Oct 21;254(4):861-7
pubmed: 18706430
PLoS Negl Trop Dis. 2017 Dec 28;11(12):e0006034
pubmed: 29283993
Cureus. 2020 Oct 24;12(10):e11132
pubmed: 33240723
Int J Clin Pract. 2021 Jul;75(7):e14182
pubmed: 33759318
JACC Clin Electrophysiol. 2021 Jan;7(1):16-25
pubmed: 33478708
N Engl J Med. 2021 Feb 11;384(6):497-511
pubmed: 33264556
N Engl J Med. 2020 May 7;382(19):1787-1799
pubmed: 32187464
J Am Coll Cardiol. 1986 Jan;7(1):142-7
pubmed: 3941202
JAMA. 2020 Dec 1;324(21):2165-2176
pubmed: 33165621
Cell Res. 2020 Mar;30(3):269-271
pubmed: 32020029
Curr Cardiol Rev. 2014 Aug;10(3):287-94
pubmed: 24827793
Clin Transl Sci. 2021 Jan;14(1):20-28
pubmed: 32888379
Circ Arrhythm Electrophysiol. 2020 Nov;13(11):e008937
pubmed: 33003964
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440
N Engl J Med. 2020 Nov 19;383(21):2041-2052
pubmed: 32706953
Antimicrob Agents Chemother. 2020 Sep 21;64(10):
pubmed: 32759267
Int J Antimicrob Agents. 2020 Jul;56(1):105949
pubmed: 32205204
Int J Infect Dis. 2021 Jan;102:389-391
pubmed: 33130195